All AbMole products are for research use only, cannot be used for human consumption.
Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is a first-in-class anti-IL-17 agent in the study of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
| Molecular Weight | 147941.89 |
| Formula | C6584H10134N1754O2042S44 |
| CAS Number | 875356-43-7 |
| Storage | -80°C for long term |
[1] Kristian Reich, et al. N Engl J Med. Bimekizumab versus Secukinumab in Plaque Psoriasis
[2] Hannah A Blair. Drugs. Secukinumab: A Review in Psoriatic Arthritis
[3] Hannah A Blair. Drugs. Secukinumab: A Review in Ankylosing Spondylitis
| Related IL Receptor/Related Products |
|---|
| IL-15-IN-1
IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM. |
| IL-17 modulator 3
IL-17 modulator 3 is an IL-17 modulator. |
| IL-17 modulator 4
IL-17 modulator 4 is a proagent of IL-17 modulator 1. |
| IL-17A modulator-3
IL-17A modulator-3 is a IL-17A modulator. |
| IL-17 modulator 4 sulfate
IL-17 modulator 4 sulfate is a proagent of IL-17 modulator 1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
